| Trial ID: | L4023 |
| Source ID: | NCT02796950
|
| Associated Drug: |
Acipimox
|
| Title: |
The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Acipimox
|
| Outcome Measures: |
Primary: Levels of GLP-1 in plasma, 9 months | Secondary: Lipolytic activity in adipose tissue by measuring FFA (free fatty acid) levels, 9 months|Insulin sensitivity by measuring blood glucose after an OGTT, 5 months | Other: Insulin secretion by measuring levels of insulin and c-peptid, 9 months|Secretion of the hormones ghrelin, leptin and GIP (gastric inhibitory polypeptide) by measuring hormone levels in plasma, 9 months
|
| Sponsor/Collaborators: |
Sponsor: University of Aarhus
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
8
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2016-06
|
| Completion Date: |
2017-01-20
|
| Results First Posted: |
|
| Last Update Posted: |
2018-05-08
|
| Locations: |
University Hospital of Aarhus, Aarhus, 8000, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02796950
|
